Solstice Advanced Materials
SOLS Nasdaq Specialty Chemicals Financials FY2023–FY2025
Solstice Advanced Materials' revenue rose 3.1% to $3.9 billion in fiscal 2025. Its net margin was 6.1%, down from 15.8% a year earlier. Free cash flow was $119 million, down 78.2%. It paid out $1.5 billion in dividends and buybacks, 1260% of free cash flow. The diluted share count rose 0.1%.
What Solstice Advanced Materials does
No business description yet.
- Legal name
- Solstice Advanced Materials Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- —
- Accession · CIK
- 0002064953-26-000008
0002064953
Revenue and margins
Solstice Advanced Materials had $3.9B of revenue in fiscal 2025, up 3.1% on the year before.
Net income and earnings per share
From fiscal 2023 to 2025, diluted EPS grew −38.3% a year. Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was $119M in fiscal 2025, 3.1% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Solstice Advanced Materials returned $1.5B to shareholders in fiscal 2025, 1,261% of free cash flow. The diluted share count rose 0.1%.
Value Solstice Advanced Materials yourself
Change the assumptions and see what they imply per share. These are models, not forecasts or price targets — the answer depends entirely on what you put in.
Discounted cash flow
Value per share
—
Adds net cash of −$1.6B and divides by 158.9M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.
Earnings multiple
Value per share
—
Reference multiples: today 39.9x · peers 20.0x · sector 20.1x.
Balance sheet
Cash, debt and the ratios that show how comfortably Solstice Advanced Materials can carry it.
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | $606M | $661M | $534M |
| Debt incl. finance leases | — | $59.0M | $2.1B |
| Net debt / EBITDA | — | −0.7x | 2.3x |
| Debt / equity | — | 0.0x | 1.5x |
| Interest coverage | 51.9x | 62.3x | 24.1x |
| Current ratio | — | 1.7x | 1.4x |
| Quick ratio | — | 1.2x | 1.0x |
| Total assets | — | $5.0B | $5.7B |
| Total liabilities | — | $1.8B | $4.3B |
| Shareholders' equity | $3.0B | $3.3B | $1.4B |
| Net debt (− = net cash) | — | −$602M | $1.6B |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | — | ✓ |
| Cash from operations is positive | ✓ | ✓ |
| Return on assets rose | — | — |
| Cash from operations exceeds net income | ✓ | ✓ |
| Debt fell relative to assets | — | — |
| Current ratio rose | — | ✕ |
| Share count didn't rise | ✓ | ✕ |
| Gross margin rose | ✕ | ✕ |
| Revenue rose relative to assets | — | — |
| F-score | — / 9 | — / 9 |
| Accruals ratio | — | −4.1% |
| Altman Z'' | 3.94 | 1.94 |
Similar companies
Each company's latest fiscal year. Fiscal years end in different months, so periods don't line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score | |
|---|---|---|---|---|---|---|---|---|
| Solstice Advanced Materials SOLS | $9.5B | 3.1% | — | 3.1% | 12.2% | 39.9x | — | |
| H.B. Fuller FUL | $2.7B | −2.7% | — | 3.5% | 6.3% | 13.8x | 7 | Compare → |
| Avient AVNT | $3.8B | 0.6% | 6.2% | 6.0% | 4.0% | 22.2x | 6 | Compare → |
| Axalta AXTA | $7.3B | −3.0% | 14.4% | 8.9% | 10.5% | 20.0x | 7 | Compare → |
| Albemarle ALB | $12.8B | −4.4% | −7.1% | 13.5% | −2.4% | — | 7 | Compare → |
3 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Revenue | $3.6B | $3.8B | $3.9B |
| Gross profit | $1.3B | $1.3B | $1.3B |
| Research and development | $81.0M | $83.0M | $97.0M |
| Interest expense | $16.0M | $13.0M | $28.0M |
| Pretax income | $814M | $797M | $647M |
| Income tax | $195M | $192M | $362M |
| Net income | $621M | $594M | $237M |
| Diluted EPS | $3.91 | $3.74 | $1.49 |
| Diluted shares | 0.16B | 0.16B | 0.16B |
| Cash flow | |||
| Cash from operations | $760M | $842M | $455M |
| Capital expenditure | $299M | $296M | $336M |
| Free cash flow | $461M | $546M | $119M |
| Depreciation and amortization | $48.0M | $39.0M | $24.0M |
| Stock-based compensation | $18.0M | $17.0M | $27.0M |
| Acquisitions | $0.0M | $0.0M | $0.0M |
| Share buybacks | $0.0M | $0.0M | $0.0M |
| Dividends paid | $0.0M | $0.0M | $1.5B |
| Dividends and buybacks | $0.0M | $0.0M | $1.5B |
| Balance sheet | |||
| Cash and short-term investments | $606M | $661M | $534M |
| Total debt | — | $59.0M | $2.0B |
| Finance lease liabilities | $0.0M | $59.0M | $118M |
| Current assets | — | $1.9B | $2.4B |
| Current liabilities | — | $1.1B | $1.7B |
| Inventory | $0.0M | $558M | $715M |
| Property and equipment, net | — | $1.7B | $2.1B |
| Total assets | — | $5.0B | $5.7B |
| Total liabilities | — | $1.8B | $4.3B |
| Shareholders' equity | $3.0B | $3.3B | $1.4B |
| Margins | |||
| Gross margin | 35.2% | 34.6% | 32.2% |
| EBITDA margin | 24.1% | 22.5% | 18.0% |
| Net margin | 17.0% | 15.8% | 6.1% |
| FCF margin | 12.6% | 14.5% | 3.1% |
| Returns | |||
| Return on capital | — | — | 12.2% |
| Return on capital employed | — | — | 17.1% |
| Return on equity | — | — | 10.2% |
| Return on assets | — | — | 4.4% |
| Growth | |||
| Revenue growth | — | 3.3% | 3.1% |
| Net income growth | — | −4.4% | −60.1% |
| EPS growth | — | −4.4% | −60.2% |
| FCF growth | — | 18.4% | −78.2% |
| Share count change | — | 0.0% | 0.1% |
| Financial health | |||
| Net debt / EBITDA | — | −0.7x | 2.3x |
| Debt / equity | — | 0.0x | 1.5x |
| Interest coverage | 51.9x | 62.3x | 24.1x |
| Current ratio | — | 1.7x | 1.4x |
| Quick ratio | — | 1.2x | 1.0x |
| Capital allocation | |||
| Capex / revenue | 8.2% | 7.9% | 8.7% |
| Stock comp / revenue | 0.5% | 0.5% | 0.7% |
| Payouts / FCF | 0.0% | 0.0% | 1,260.5% |
| Quality scores | |||
| Altman Z'' | — | 3.9 | 1.9 |
| Accruals ratio | — | — | −4.1% |
Source: SEC EDGAR XBRL filings (CIK 0002064953). Data updated October 14, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.